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Abstract
Adaptive seamless designs combine confirmatory testing, a domain of phase III trials, with features
such as treatment or subgroup selection, typically associated with phase II trials. They promise to in-
crease the efficiency of development programmes of new drugs, e.g. in terms of sample size and / or
development time. It is well acknowledged that adaptive designs are more involved from a logistical
perspective and require more upfront planning, often in form of extensive simulation studies, than con-
ventional approaches. Here we present a framework for adaptive treatment and subgroup selection using
the same notation, which links the somewhat disparate literature on treatment selection on one side and
on subgroup selection on the other. Furthermore, we introduce a flexible and yet efficient simulation
model that serves both designs. As primary endpoints often take a long time to observe, interim anal-
yses are frequently informed by early outcomes. Therefore, all methods presented accommodate both,
interim analyses informed by the primary outcome or an early outcome. The R package asd, previously
developed to simulate designs with treatment selection, was extended to include subpopulation selection
(so-called adaptive enrichment designs). Here we describe the functionality of the R package asd and
use it to present some worked-up examples motivated by clinical trials in chronic obstructive pulmonary
disease and oncology. The examples illustrate various features of the R package providing at the same
time insights into the operating characteristics of adaptive seamless studies.
Keywords: Adaptive design; Clinical trials; Closed test procedure; Combination test; Dunnett test
1 Introduction
There is a long history of application of sequential methods in clinical trials that allow the monitoring of
accumulating data at a series of interim analyses (Jennison and Turnbull, 1999; Whitehead, 1997). Whilst
most early work focussed on the aim of stopping the trial as soon as sufficient evidence has been obtained,
this body of work has rapidly expanded to include the use of interim data for other design adaptations,
including sample size reestimation (Friede and Kieser, 2006; Proschan, 2009). Over the past years, there
has been considerable interest in using interim analyses for selection of treatments, with less effective
treatments dropped from the study, or for selection of patient subgroups, with recruitment following an
interim analysis limited to subgroup(s) in which a promising effect is indicated (Bauer et al, 2016; Pallmann
et al, 2018).
A major statistical challenge in the development of such methods is the control of the type I error rate
when adaptations are made on the basis of data that will also be included in the final analysis. For treatment
selection, most methods proposed fall into two groups. The first builds on the work of Thall et al. (1988,
1989) using the group-sequential method, but require that a single treatment continues along with a control
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beyond the first stage (Stallard and Todd, 2003) or that the number of treatments at each stage is specified
in advance (Stallard and Friede, 2008). The second group of methods is based on the combination test
approach of Bauer and Ko¨hne (1994). Such methods are more flexible (see, for example, Bauer and Kieser
(1999), Posch et al (2005), and Bretz et al (2006)), but may be less powerful in some settings (Friede
and Stallard, 2008). Magirr et al. (2012) proposed a group-sequential method that does allow completely
flexible treatment selection, though this may be at the cost of conservatism and an associated loss in power.
Koenig et al (2008) showed how the conditional error principle of Mu¨ller and Scha¨fer (2001) may be used
to extend the Dunnett test (Dunnett, 1955) to a two-stage design with flexible treatment selection. This has
been shown to compare well in terms of power with competing methods (Friede and Stallard, 2008).
There is a smaller body of work on clinical trials with subgroup selection (see Brannath et al (2009);
Jenkins et al (2011); Wassmer and Dragalin (2015)). This has mainly used the combination testing ap-
proach, though methods based on the conditional error principle (Friede et al, 2012; Stallard et al, 2014;
Placzek and Friede, 2018) and the group-sequential approach (Magnusson and Turnbull , 2013) have also
been proposed. An overview is provided in Ondra et al (2016).
Earlier work had assumed that the adaptations would be informed by the primary outcome, which is
also used for hypothesis testing. From a practical perspective, however, this can be a strong limitation.
In particular in chronic diseases clinically meaningful endpoints might take some time to observe, which
means that most or all patients are recruited by the time the primary outcome is observed for the first
patients. This is illustrated for example by Chataway et al (2011) in the context of secondary progressive
multiple sclerosis. As a consequence, adaptations need to be based on early outcomes for adaptive desings
to be feasible in these situations. Therefore, some adaptive seamless designs have been extended to allow
the use of short-term endpoint data for decision making at interim (Stallard, 2010; Friede et al, 2011; Jenkins
et al, 2011; Friede et al, 2012; Kunz et al, 2014, 2015; Stallard et al, 2015).
It is acknowledged that these more complex designs require intensive simulation studies in the planning
to evaluate their operating characteristics (Benda et al, 2010; Friede et al, 2010). A limitation to the use of
adaptive methods in practical applications is often the availability of software to enable construction and
evaluation of appropriate study designs and to conduct the final analysis. A number of commercial software
packages including ADDPLAN and EAST are available for this purpose. Although some R packages for
group-sequential designs including including gsDesign and gscounts and adaptive group-sequential
designs such as rpact are available from CRAN, there is still a shortage of comprehensive freely available
software for adaptive seamless designs with treatment or subgroup selection, with the exception of the R
package asd developed to plan clinical trials with treatment selection (Parsons et al, 2012).
The aim of this paper is to present the approaches for treatment and subgroup selection in a unified
notation. By expressing the subgroup selection problem in a similar setting to that of treatment selection,
the R package asd, originally developed for treatment selection, can be used for designs of both types. The
methods implemented are based on the combination testing approach. Therefore, the designs obtained are
fully flexible, controlling the type I error rate for any data-driven adaptation (treatment / subgroup selection
as well as sample size adaptation).
Although the employed test procedures do not make use of the joint distribution of the tests statistics,
we derive the joint distribution to develop a fairly general and efficient simulation model. This is based
on standardized test statistics only requiring the assumption of multivariate normal distributions for the test
statistics, but not the individual observations. Furthermore, early outcomes informing the interim decisions
are incorporated, since this is often important in practice as explained above. The application of the methods
using the R package asd will be illustrated by clinical trials in chronic obstructive pulmonary disease
(COPD) and oncology with treatment and subgroup selection, respectively.
2 Methods
2.1 Notation and hypotheses
We consider first the setting of treatment selection designs. The study is conducted in up to J ≥ 2 stages.
In the first stage, patients are randomised between K experimental treatments and a control treatment. In
a general setting, suppose that observations of the primary outcome from group k, k = 0, . . . ,K , where
k = 0 corresponds to the control group, have a distribution depending on some parameter µk, and that it is
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desired to test the family of hypothesesHk : θk = 0, k = 1, . . . ,K , where θk = µk − µ0. Let pkj denote
a p-value for the test of hypothesisHk based on the data from patients first observed in stage j. These data
may not be available at the time of the interim analysis following stage j, but become available only later
on in the trial (Friede et al, 2011). As we will explain in Section 2.2 below, the interim decisions need not
necessarily be based on the primary outcome but could, in principle, make use of any available outcome
while still maintaining control of the type I error rate.
Next we consider the setting of subgroup selection designs. Suppose that a single experimental treat-
ment is to be compared with a control but that patients can be categorised as belonging to one or more
predefined subgroups. Interest is focused on the treatment effect in the full population and each subgroup,
in particular in the subgroup with the largest treatment effect.
As part of the aim of this paper is to make explicit the similarities between methodology for treatment
and subgroup selection designs, we will use similar notation for both settings when this does not cause
confusion. Thus suppose that observations come from patients in K subgroups labeled k, k = 1, . . . ,K .
Suppose that data for patients in subgroup k receiving treatment r, r = 0, 1 have a distribution depending
on some parameter µkr . Setting θk = µk1 − µk0, it is desired to test the family of hypothesesHk : θk = 0,
k = 1, . . . ,K . As above, pkj denotes a p-value for the test of hypothesisHk based on the data from patients
with an outcome first observed in stage j.
2.2 Interim selection rules
The testing strategies described here control the type I error rate for any selection rule, but it is good practice
to specify selection rules in advance to enable calculation of operating characteristics including sample size
and power. In the following we introduce some possible examples of interim selection rules based on the
final outcome, but understand that these could equally be applied to an early outcome as we will explain
below.
One obvious way to proceed would be to select the treatment or subpopulation which performs best in
terms of some statistic Zj,k (where Zj,k is some estimator of θk following stage j). However, this might not
be wise in situations where sample sizes are relatively small given the differences between the treatments,
since there is a rather high risk of picking some other but the optimal treatment or subpopulation. The
so-called ǫ-rule proposed by Kelly et al (2005) selects all treatments or subpopulations with statistics Zj,k
for which Zj,k ≥ maxi Zj,i − ǫ (assuming that larger values of Zj,k are better). For ǫ = 0 this rule reduces
to selecting the maximum only. For large ǫ no selection takes place as all treatments or subgroups are
carried forward. Otherwise varying numbers of treatments or subpopulations are carried forward into the
next stage.
Multi-arm studies including several doses of an experimental drug motivate another selection rule. In
some indications it is not uncommon to select not one but two doses for confirmatory testing in phase III.
The COPD study discussed in more detail in Section 5 is a good example for this. A more generalized
version of this rule would be to select the bestK⋆ out ofK treatments or subpopulations whereK⋆ would
be specified in advance.
The selection of treatments or subgroups in interim analyses could be informed by the primary outcome
or, if this is not feasible, by an early outcome. The early outcome must not necessarily fulfill all require-
ments of a surrogate endpoint (Burzykowski et al, 2005) as weaker conditions might suffice. Chataway et
al (2011) coined the phrase of a “biologically plausible” outcome that “gives some indication as to whether
the mechanism of action of a test treatment is working as anticipated”. Nevertheless, for the operating char-
acteristics of the adaptive seamless design the correlation between the early and the final outcomes on an
individual patient level as well as the treatment effects on both the early and the final outcome (population
level) are relevant as we will see below.
2.3 Error rate control via the closed testing procedure
In either the treatment selection or the subgroup selection setting, the problem has been posed in such a
way that it is desired to test the null hypotheses Hk : θk ≤ 0, k = 1, . . . ,K . It is desirable to conduct
these hypothesis tests such as to control the familywise error rate in the strong sense, that is control of the
probability of rejection of any true hypothesis within this family, at some specified level, α. Strong error
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rate control my be achieved through a closed testing procedure in which, denoting byHK the intersection
hypothesis ∩k∈K Hk, all hypotheses HK for K ⊆ {1, . . . , k} are tested at nominal level α, and Hk
rejected if and only if HK is rejected at this level for all K ∋ k (Marcus et al, 1976).
Application of the closed testing procedure requires a test of the intersection hypothesis HK for each
K ⊆ {1, . . . , k}. These hypothesis tests must also combine evidence from the different stages in the trial.
This may be achieved through the use of a combination testing method, as described in detail in the next
subsection.
2.4 The combination testing method and early stopping
Extending the notation introduced above, let pK j denote a p-value for a test of the hypothesisHK based on
data from patients with an outcome first observed at stage j. By construction, underHK , pK j ∼ U [0, 1],
or if a conservative test is used, pK j is stochastically no smaller than a U [0, 1], for all j and K . We also
assume that the conditional distribution of pK j given pK 1, . . . , pK j−1 is stochastically no smaller than a
uniform for all pK 1, . . . , pK j−1 for all j, which is also referred to as the p-clud condition (Brannath et al,
2002). The condition is satisfied if the p-values from different stages are independent.
The p-values from the different stages can be combined using a number of combination functions (Bauer
and Ko¨hne, 1994; Lehmacher andWassmer, 1999) to give test statistics CK j(pK 1, . . . , pK j) which, given
the assumptions above regarding the distributions of the p-values, have known distributions under HK
irrespective of adaptations made to the study design. These test statistics may thus be used as the basis of a
test of hypothesisHK (Bauer and Kieser, 1999; Bretz et al, 2006).
Although a number of combination functions have been proposed, we will use the inverse normal
combination function (Lehmacher and Wassmer, 1999), which is equivalent to the method of Cui et al
(1999). This gives test statistics CK j =
∑j
j′=1 wj′Φ
−1(1 − pK j′) where w1, . . . , wJ are specified
in advance. Given the distributional assumptions under HK , CK j are distributed as, or are stochasti-
cally no larger than, a multivariate normal distribution with mean zero, var(CK j) = w
2
1 + · · · + w
2
j and
cov(CK j , CK j′) = w
2
1 + · · ·+ w
2
min{j,j′}.
Following Posch et al (2005) we assume that hypotheses once they are dropped cannot be rejected
anymore, which results in conservative tests. Furthermore, applying the closed testing principle outlined in
Section 2.3 in an adaptive design the p-value pK j is replaced by pK ∩Ijj whereIj is the set of hypotheses
carried forward into stage j (Posch et al, 2005).
If interim analyses are used for adaptation of the design but not for stopping the trial, a final test
of HK may be based on CK J . More generally, a sequential test of HK may be conducted based on
the joint distribution of CK 1, . . . , CK J , rejecting HK if CK j ≥ uK j for some critical values uK =
(uK 1, . . . , uK J)
T . To simplify the notation, uK and uK j will generally be written as u and uj when it is
clear which hypothesis is being tested. The single constraint that the overall error rate should be at most α
is insufficient to determine u uniquely. A common approach in sequential analysis is to specify the type I
error to be spent at each interim analysis, and to find uK 1, . . . , uK J to satisfy
prHK (CK j′ ≥ uK j′ , some j
′ ≤ j) = α∗j (1)
where α∗1 ≤ · · · ≤ α
∗
J = α are either specified in advance (Slud and Wei, 1982) or depend on the observed
information in some predeterminedway (Lan and DeMets, 1983). Critical values uK 1, . . . , uK J satisfying
(1) can be found recursively with uK j found directly from the joint distribution of CHK 1, . . . , CHK J via a
numerical search once uK 1, . . . , uK j−1 are known. Computational details are given by e.g. Jennison and
Turnbull (1999).
Construction of the test statistics CK 1, . . . , CK J , on which the sequential test is based, requires spec-
ification of p-values pK 1, . . . , pK J for testing HK . For elementary hypotheses, that is when |K | = 1,
pK j can be obtained from a standard test, such as a t-test for normally distributed data or a chi-squared
test for binary data. When |K | > 1, pK j should be calculated so as to allow for the multiple comparisons
implicit in testing HK . In the treatment selection setting, as comparisons are with a common control, a
Dunnett test (Dunnett, 1955) may be used. In the subgroup selection setting, the simple Bonferroni proce-
dure, Simes’ procedure (Brannath et al, 2009) or the Spiessens-Debois test (Spiessens and Debois, 2010), a
Dunnett-type test with a generalized covariance structure, may be used. In each case the level of adjustment
depends on the size of K .
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3 Simulation model
As eluded to in the Introduction, simulations are often required in the planning phase of a study to chose cer-
tain design options such as sample sizes or interim selection rules. Here we propose a simulation model that
is efficient in the sense that population statistics are generated rather than individual patient data. Therefore,
computation times do not increase with larger sample sizes.
In a wide variety of settings it is possible to obtain statistics that are, at least asymptotically, normally
distributed with known variance. When a series of interim analyses is conducted, these statistics have a
multivariate normal distribution, with statistics obtained at different interim analyses correlated because of
the use of earlier data in later stages. In the setting of treatment or subgroup selection, these multivariate
normal distributions may be extended to give the joint distribution of statistics corresponding to different
treatment comparisons or for treatment effects in different subgroups. To be clear, these statistics are not
actually necessarily the test statistics used to test the hypotheses but are rather some estimator of θk. Also
the distributional forms assumed in the simulations need not be used as the basis of hypothesis tests, since
these, as described in Section 2.4, can use the combination testing approach.
Since, as indicated above, we will also be considering adaptations to the trial design based on the
observation of short-term endpoint data, it is helpful to further extend the simulation models to include
test statistics calculated based on different endpoints. The distributions of the resulting test statistics are
described briefly in this section. Additional detail is given in the appendix.
3.1 Treatment selection
We consider first treatment selection designs. Let θˆkj denote the estimate of the treatment effect, θk, for
treatment k based on the data available at the jth interim analysis, and I−1kj denote the variance of this
estimate. As these estimates are often, at least asymptotically normally distributed, our model will be based
on an assumption of this distributional form. Assume that Ikj does not depend on k, and so may be denoted
by Ij , and that the correlation between different treatment comparisons with a common control group is
1/(1 + λ), as will often be the case if we have 1 : λ randomisation. Setting Skj = θˆkjIkj , we then have
(S11, . . . , SK1, . . . , S1J , . . . , SKJ)
′ ∼ N
(
I ⊗ θ,Σ(GS)(I)⊗ Σ
(CS)
K (
1
1 + λ
)
)
where I and θ denote respectively the vectors (I1, . . . , IJ )
′, and (θ1, . . . , θK)
′ and
Σ
(CS)
K (r) =


1 r · · · r
r 1
. . .
...
...
. . .
. . . r
r · · · r 1


and
Σ(GS)(I)(1) =


I
(1)
1 I
(1)
1 · · · I
(1)
1
I
(1)
1 I
(1)
2 · · · I
(1)
2
...
...
. . .
...
I
(1)
1 I
(1)
2 · · · I
(1)
J


denote variance matrices of the K ×K complex symmetric form and of that obtained in the usual group-
sequential setting.
3.2 Subgroup selection
In the subgroup selection setting, let θˆkj denote the estimate of the treatment effect, θk, for subgroup k
based on the data available at the jth interim analysis. Again, assume that these estimates are normally
distributed, let I−1kj denote the variance of this estimate and assume that Ikj does not depend on k, and so
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may be denoted by Ij . In the simplest case, in which K = 2 and subgroup 2 is the whole population and
subgroup 1 a proportion of size τ , setting Skj = θˆkjIkj , we have
(S11, S21, . . . , S1J , S2J )
′ ∼ N
(
I ⊗ θ,Σ(GS)(I)⊗ Σ(GS)
(
τ
1
))
.
Extensions to the case when a short-term endpoint is also considered, and to more complex subgroup
selection settings are discussed in the appendix.
4 Software implementation in R
4.1 R package asd
The simulation models for two-stage treatment selection and subgroup selection designs, described in Sec-
tion 3, can be implemented in the R (R Development Core Team, 2009) package asd (Parsons et al, 2012),
which is available from the Comprehensive R Archive Network (CRAN) at http://cran.r-project
.org/package=asd). This package comprises a number of functions that allow the properties of seam-
less phase II/III clinical trial designs, potentially using early outcomes, for treatment or subgroup selection
to be explored and evaluated prior to a study commencing. An earlier version of this package, without the
extension to subgroup designs, enhanced options for a wider range of outcome measures and more com-
plete output model description was described previously by Parsons et al (2012). The general structure of
the code comprises a set of base functions that implement lower level tasks such as hypothesis testing, treat-
ment selection and closed testing procedures. The base functions, which have been described previously in
the setting of treatment selection designs (Parsons et al, 2012), have been modified in the latest version of
the asd package to work with both subgroup and treatment selection designs. The higher level user facing
function asd.sim has been replaced by two new functions treatsel.sim and subpop.sim that are
called directly by the user to implement hypothesis testing and simulations. The more general functions,
gtreatsel.sim and gsubpop.sim can in principle be called directly by the user, although due to the
more complex input structure this is generally not recommended.
4.2 Function subpop.sim
Friede et al (2012) extended the previously described CT approaches, for co-primary analyses in a single
pre-defined subgroup and the full population, using the methods proposed by Spiessens and Debois (2010)
to control the FWER in the subgroup and the full population, and also proposed a novel method to obtain
a critical value for the definitive test using a CEF approach; full details of these methods are given by
Friede et al (2012). The function subpop.sim implements all the methods for subgroup selection in
adaptive clinical trials reported by Friede et al (2012) and subsequent correspondence (Friede et al, 2013).
The authors described and explored the performance of a number of methods in the setting described here,
distinguishing between two distinct approaches to control the familywise error rate (FWER), a combination
test (CT) method (Brannath et al, 2009; Jenkins et al, 2011) and a conditional error function method (CEF).
4.2.1 Input arguments
An overview and brief description of the input arguments available for subpop.sim is shown in Ta-
ble 1. The combination test (CT) methodology described by Friede et al (2012) can be implemented in
subpop.sim using either the Spiessens and Debois (2010) (SD), Simes or Bonferroni testing proce-
dures to control the FWER. These and the CEF approach can be selected using the method argument to
subpop.sim using the following options; (i) CT-SD (method="CT-SD"), (ii) CT-Simes (method="CT-Simes"),
(iii) CT-Bonferroni (method="CT-Bonferroni") and (iv) CEF (method ="CEF").
The syntax providing the group sample sizes, for stages 1 and 2, for a putative trial design and effect
sizes for early and final outcomes is consistent across the available outcome types and comprises a list of
the selected options. For instance, for a design where the required sample size per treatment arm is 100
for stage 1 and 200 for stage 2 would be implemented using the following expression, n=list(stage1=
100,stage2=200). The assumption, in the current version of asd, is that the sample size in the control
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arm of the study is the same as in the treatment arm. The default setting is that if the subgroup only is
selected at the interim analysis at stage 1, then the sample size in this group is the same as it would be if
the study continued with the full population. If an increase in the sample size in the subgroup were planned
if this group only were selected (enrichment) then this can be implemented by adding an additional item
to the list to indicate this; for instance, if we wanted a sample size of 200 in the subgroup in this setting,
irrespective of the subgroup prevalence, then we would modify the previous argument to the following
n=list(stage1=100,enrich=200,stage2=200).
Effect sizes for early and final outcomes are also given as a list using expressions of the following
structure, where the first element of each vector is the effect size in the subgroup and the second element is
the effect size in the full population, effect=list(early=c(0.3,0.1),final=c(0.3,0.1)).
So here we are assuming an effect size of 0.3 in the subgroup and 0.1 in the full population; the effect size
in the control group is set by default to be zero. The default setting is for normal outcomes for both early
and final outcomes, outcome=list(early="N",final="N"), and the effects are interpreted given
these options. The allowed options for outcome types are normal (N), time-to-event (T) and binary (B), and
all combinations of these are allowed for early and final outcome measures. Generally, it is assumed that
higher means (N) and lower event rates (B or T) are better. A detailed description of these options is left for
the following section describing function treatsel.sim; the options described there are analogous to
those available for subpop.sim. In the simpler setting where group selection is based purely on the final
outcome is required, this can be implemented by setting the effect sizes for the early and final outcomes to
be equal and setting the correlation between the early and final outcomes to one (i.e. corr=1).
The subgroup prevalence is set by a single argument (sprev), where for instance sprev=0.5 indi-
cates that the subgroup comprises half of the full population. The function subpop.sim randomly gener-
ates test statistics (with a seed number set using seed) and accumulates results from usually a large number
of simulations that must be set using the nsim option (default setting, nsim=1000). The prevalence can
be either fixed at the set value (sprev.fixed=TRUE) or allowed to vary (sprev.fixed=FALSE) us-
ing a single realization of the binomial random variate generation function rbinom, at the set values for
the sample size and subgroup prevalence, at each simulation.
Subgroup selection at interim is implemented using the so-called threshold selection rule (Friede and
Stallard, 2008; Friede et al, 2012) (select="thresh"), that is such that if the difference between the test
statistics for the subgroup and the full population∆ ≤ l1 then the subgroup only is tested at the end of stage
2, if ∆ > l2 the full population only is tested and otherwise both subgroup and full populations are tested.
The threshold rule limits (l1, l2) are set using the argument selim which is a vector of standard deviation
multiples; if for instance large limits are set (e.g. selim=c(-10,10)) then both subgroup and full
populations will always be tested at the trial endpoint, whereas if selim=c(0,0) only the test regarding
the population with the largest test statistic at interim is taken into stage 2. Intermediate values for selim
between these extremes providemore flexible selection options. The weight for the CT approaches, if unset,
is given by nstage1/(nstage1 + nstage2) and the test level is set by default to 0.025 (level=0.025).
4.2.2 Output
The output to subpop.sim first gives a summary of the simulation model, including expected values
for the test statistics at each stage of the study. The main summary table reports the number of times
that hypotheses H
{S}
0 , H
{F}
0 , H
{S,F}
0 were selected for testing and rejected when the subgroup (S), the
full population (F ) or both were tested. Output from subpop.sim is by default directed to the usual
R console, but to save more detailed summaries of the simulation model, output can be directed to a file
using this as an argument to the file function (e.g. file="output.txt"). Section 5 shows how
subpop.sim is used in a practical setting with example data.
4.3 Function treatsel.sim
Functiontreatsel.sim replaces and generalizes the previous functionasd.sim, with the name change
made to make it much more explicit that the code implements only simulations for treatment selection de-
signs for multi-arm studies. Much of the syntax and model set-up is consistent between treatsel.sim
and subpop.sim.
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Table 1: Brief description and available input arguments to R functions subpop.sim and
treatsel.sim
Argument Description
n List giving sample sizes for each treatment group at stage 1 (interim) and stage 2
(final) analyses; subpop.sim has an additional optional list item for enrichment
effect List giving effect sizes for early and final outcomes; an optional control argument
can also be included for subpop.sim
outcome List giving outcome type for early and final outcomes; options for normal (N), time-
to-event (T) and binary (B) are currently available
nsim Number of simulations (nsim< 1× 107)
sprev Subgroup prevalence (0 <sprev< 1); for function subpop.sim only
sprev.fixed Subgroup prevalence can be either fixed or allow to vary at each simulation (TRUE or
FALSE); for function subpop.sim only
corr Correlation between early and final outcomes (−1 ≤corr≤ 1)
seed Seed number for simulations
select Method for treatment selection; for subpop.sim a threshold rule with limits using
argument selim and for treatsel.sim one of seven available options (see text)
with additional arguments epsilon and thresh as necessary
ptest A vector of treatments for specific counts of the number of rejections; for function
treatsel.sim only
method Methodology used for simulations; for treatsel.sim either invnorm or
fisher and for subpop.sim either CT-SD, CT-Simes, CT-Bonferroni or
CEF (see text)
fu Follow-up options (TRUE or FALSE); for function treatsel.sim only
weight User defined stage 1 weight (0 ≤weight≤ 1)
level Test level for simulations (0 ≤level≤ 1)
file File name to dump output; if unset will default to R console
4.3.1 Input arguments
An overview and brief description of the input arguments available for treatsel.sim is shown in Table
1. One aspect of the design set-up that differs considerably between treatsel.sim and subpop.sim
is the coding of the treatment effects. Treatment effect sizes are given for the control group θ0 and the test
treatment or treatments θk and as vectors for both early and final outcomes; for instance effect=list(
early=c(0,0.1,0.2,0.1), final=c(0,0.1,0.2,0.3)) indicates that there are three test treat-
ments with effect sizes 0.1, 0.2 and 0.1 for the early outcome and 0.1, 0.2 and 0.3 for the final outcome re-
spectively; the control is set to 0 for both outcomes. There is no limit to the number of test treatment groups.
However, in practice our experience is that the code runs slowly for designs with eight or more treatment
groups. The setting of the effect sizes can be clarified further by considering the available options for the
outcome types (normalN, time to eventT, and binary B), set using the option outcome, with the default be-
ing to have both early and final outcomes normal (outcome=list(early="N",final="N")), with
all nine combinations available. Generally, it is assumed that higher means (N) and lower event rates (B or
T) are better.
For normal outcomes the test statistics for the simulation model for theK test treatments, relative to the
control group, are given by
√
n/2× (θk−θ0). For time-to-event outcomes, effects are interpreted as minus
log hazard rates, with the control θ0 set to zero and test statistics are given by
√
ok/4 × (θk − θ0), where
the expected total number of events in the control and treatment groups ok for treatment k is calculated
under an assumed exponential model to be n × (1− exp(− exp(−θ0))) + n × (1− exp(− exp(−θk))).
Binary effects are characterized by log odds ratios,
√
1/ok + 1/(n− ok) + 1/o0 + 1/(n− o0)×(θk−θ0),
where θk is minus the log odds of the event and the observed number of events in treatment group k is
ok = n × 1/(1 + exp(θk)). Some care must be taken when setting-up the simulation model, as clearly
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the interpretation of the effect argument to treatsel.sim is dependent on the options selected for
outcome.
The method argument to treatsel.sim allows either the inverse normal (invnorm) or Fisher’s
(fisher) combination test and the logical follow-up argument (fu) determines whether (i) patients in the
dropped treatment groups are removed from the trial and unknown test statistics in the dropped treatments
are set to −∞ at stage 2 (fu=FALSE) or (ii) patients are kept in the trial and followed-up to the final out-
come, in the same manner as the patients recruited in stage 1 in the selected treatment groups (fu=TRUE);
Friede et al (2011) called option (i), the default setting, discontinued follow-up and option (ii) complete
follow-up. Seven treatment selection rules based on stage 1 test statistics are available in treatsel.sim,
and are chosen with the select argument; (i) select all treatments (select=0), (ii) select the maximum
(select=1), (iii) select the maximum two (select=2), (iv) select the maximum three (select=3), (v)
flexible treatment selection using the ǫ-rule (Friede and Stallard, 2008; Friede et al, 2011), with additional
argument (epsilon) (select=4), (vi) randomly select a single treatment (select=5) or (vii) select all
treatments greater than a threshold, with the additional argument (thresh) (select=6).
The only additional argument available for treatsel.sim, that has not been covered in the section
describing subpop.sim, is ptest. This is a vector of valid treatment numbers for determining specific
counts for the number of simulations that reject the null hypothesis; for instance, for three test treatments
and ptest=c(1,3), treatsel.sim will count and report the number of rejections of one or both
hypotheses for testing treatments 1 and 3 against the control, in addition to the number of rejections of each
of the elementary hypotheses.
4.3.2 Output
The output from treatsel.sim first gives a summary of the simulation model, including expected
values for the test statistics at each stage of the study. The main summary tables reports (i) the num-
ber of treatments selected at stage 1, (ii) treatment selection at stage 1, that is how often each treatment
was selected, (iii) counts of hypotheses rejected at study endpoint, for each of the elementary hypothe-
ses (H
{1}
0 , H
{2}
0 , . . . , H
{K}
0 ) and (iv) the number of times that one or more than one of the hypotheses
identified in ptest is rejected. Section 5 shows how treatsel.sim is used in a practical setting with
example data.
5 Examples
In this section we illustrate the methods described above by two example studies using the R package
asd. The first is a multi-arm randomised controlled trial in COPD with treatment selection; which will be
considered in Section 5.1. As a second example we consider trials in oncology with time-to-event outcomes
and subgroup selection; this will be considered in Section 5.2.
5.1 Clinical trial in COPD with treatment selection
Barnes et al (2011) and Donohue et al (2010) report a seamless adaptive design with dose selection, which
was also discussed elsewhere (Cuffe et al, 2014). Patients were randomized to four doses of indacaterol
(75µg, 150µg, 300µg and 600µg), active controls and placebo control. For the purpose of illustration,
we ignore the active controls in the following and use the observed results to illustrate the design process.
The primary outcome was the percentage of days of poor control over 26 weeks. As recruitment for the
entire study took only 6 months, the interim treatment selection could not be based on the primary end-
point. Trough forced expiratory volume in 1 second (FEV1) at 15 days was identified as a suitable early
outcome to inform the interim analysis. From Figure 1 of Barnes et al (2011), difference in trough FEV1
compared to placebo at 15 days is 150ml, 180ml, 210ml and 200ml for the indacaterol doses 75µg, 150µg,
300µg and 600µg, respectively. Reported 95% confidence intervals suggest 2 standard errors of treatment
difference is approximately 60ml, so assuming equal stage 1 sample sizes n1=110, then the standard devi-
ation of the measurements is approximately 220ml. Standardized effect sizes are thus approximately 0.68,
0.82, 0.95 and 0.91 for the indacaterol doses 75µg, 150µg, 300µg and 600µg, respectively. Regarding
the final outcome days of poor control (%) over 26 weeks, we gather from the report of stage 2 results at
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http://clinicaltrials.gov/show/NCT00463567 that the placebo rate was 35%. Let us assume rates of 31%,
30%, 28% and 29% for the four doses of indacaterol (75µg, 150µg, 300µg and 600µg). Based on reported
standard errors, we estimate the standard deviation to be approximately 30%. Hence, the standardized ef-
fect sizes are approximately 0.13 (75µg), 0.17 (150µg), 0.23 (300µg) and 0.20 (600µg). The approximate
sample sizes per arm were 100 patients in stage 1 and 300 patients in stage 2. Since the aim was to select
two doses of indacaterol at the interim analysis to take into stage 2, we consider an overall sample size for
the two stage of 5× 100+ 3× 300 = 1400 patients. Furthermore, a moderate positive correlation between
early and final outcomes of 0.4 is assumed.
In the following we will consider three settings: (i) continuous early and final outcomes and selecting
always two doses for the second stage, as in the original study; (ii) continuous early and final outcomes, as
in the original study, but for the purpose of illustration we vary the selection rule using the threshold rule to
allow varying numbers of doses being taken forward for confirmatory testing in the second stage; (iii) as in
particular final outcomes are non-normal and early and final outcomes are on different scales we assume in
another setting that the final is binary and not continuous.
5.1.1 Continuous early and final outcomes: Selecting always two doses for the second stage
As an example we consider a fixed total sample size of 1400 patients, which we can allocate between the
two stages, with either more or less resources for each stage. We consider the following combinations of
n1 = 10, 25, . . . , 175 and n2 = 450, 425, . . . , 175 with 5 × n1 + 3 × n2 = 1400. Each one of these
sample size options can be tested using the following implementation of the treatsel.sim function for
the setting with 100 patients per arm in stage 1 and 300 patients per arm in stage 2:
treatsel.sim(n=list(stage1=100,stage2=300),
effect=list(early=c(0,0.68,0.82,0.95,0.91),
final=c(0,0.13,0.17,0.23,0.20)),
outcome=list(early="N",final="N"),
nsim=10000,corr=0.4,seed=145514,select=2,
level=0.025,ptest=c(3,4))
This code sets the sample sizes for each stage, and provides the effect estimates as described above,
for a normal early outcome (“N”) and a normal (“N”) final outcome. The correlation is set to 0.4, and the
number of simulations to 10,000. The select=2 options implements the rule that chooses the two treatments
with the largest test statistics an interim. The test level is set to 0.025 and the ptest options allows us to
count rejections for either or both of the doses 300µg and 600µg. Results from running this code are as
follows (omitting the parts describing the setup):
simulation of test statistics:
expectation early = 4.8 5.8 6.7 6.4
expectation final stage 1 = 0.9 1.2 1.6 1.4 and stage 2 = 1.6 2.1 2.8 2.4
weights: stage 1 = 0.5 and stage 2 = 0.87
number of treatments selected at stage 1:
n %
1 0 0.00
2 10000 100.00
3 0 0.00
4 0 0.00
Total 10000 100.00
treatment selection at stage 1:
n %
1 383 3.83
2 3282 32.82
3 8661 86.61
4 7674 76.74
hypothesis rejection at study endpoint:
n %
H1 183 1.83
10
H2 2067 20.67
H3 7206 72.06
H4 5541 55.41
reject H3 and/or H4 = 8469 : 84.69%
The first part of the output provides a summary of the model set-up, and the second part values of the test
statistics used in the simulations. The squared weights are calculated, in this case, as 100/400 and 300/400.
The results are summarized in the three lower tables. The first indicates that two treatments were always
selected at stage 1, the second gives the number of simulations that each treatment was selected and the third
gives the number of simulations that the elementary hypotheses were rejected. The final statement gives
the number of simulations that at least one of the treatments picked using the ptest options were rejected.
Assigning the output for this function to an object that we for the sake of illustration call simply output, then
the summaries described here can be accessed directly, for instance for plotting data or other analysis, us-
ing the syntax output$count.total, output$select.total, output$reject.total and
output$sim.reject.
The results of the simulations suggest that given the large treatment effects on the early outcome (trough
FEV1 at 15 days), and the modest effects on the final outcome (days of poor control (%) over 26 weeks),
the greatest power would have been achieved by using a sample size of around 50 per group in stage 1 (see
Figure 1).
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Figure 1: Probability of rejection of at least one elementary hypothesis (◦; solid line), and selection proba-
bilities (dashed lines) for stage 1 sample sizes in range 10 to 175 per group.
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5.1.2 Continuous early and final outcomes: Selecting varying numbers of doses for the second stage
As an alternative to always selecting the best two performing treatments at interim, we now consider a
threshold rule, where all treatments with test statistics at interim analysis above a fixed threshold are taken
into stage 2. If no treatments reach the threshold, the study is stopped for futility. Simulations are imple-
mented using the same effect sizes as in setting 1, a stage 1 sample size of 40 and a stage 2 sample size of
400 in the following code for a threshold of 3:
treatsel.sim(n=list(stage1=40,stage2=400),
effect=list(early=c(0,0.68,0.82,0.95,0.91),
final= c(0,0.13,0.17,0.23,0.20)),
outcome=list(early="N",final="N"),
nsim=10000,corr=0.4,seed=145514,select=6,
thresh=3,level=0.025,ptest=c(3,4))
The “select=6” options implements the threshold rule, with the fixed early outcome test statistic
threshold set using the “thresh” option. Results from running this code are as follows (omitting the parts
describing the setup):
simulation of test statistics:
expectation early = 3 3.7 4.2 4.1
expectation final stage 1 = 0.6 0.8 1 0.9 and stage 2 = 1.8 2.4 3.3 2.8
weights: stage 1 = 0.3 and stage 2 = 0.95
number of treatments selected at stage 1:
n %
1 800 8.00
2 1634 16.34
3 3098 30.98
4 4175 41.75
Total 9707 97.07
treatment selection at stage 1:
n %
1 5083 50.83
2 7469 74.69
3 8914 89.14
4 8596 85.96
hypothesis rejection at study endpoint:
n %
H1 2480 24.80
H2 4882 48.82
H3 7769 77.69
H4 6642 66.42
reject H3 and/or H4 = 8600 : 86%
The output shows that this design was stopped for futility only 3% of the time; with all four experimental
treatments being taken into stage 2 more than 41% of the time. Running the above code for thresholds in
the range 0 to 6 (at intervals of a half) and extracting output for each option gives the results summarized in
Figure 2.
The expected overall sample sizes for the scenarios in Figure 2, based on the simulated number of
treatments selected at stage 1 and the fixed stage 1 and stage 2 sample sizes of 40 and 400, are as follows;
2199.5, 2197.3, 2188.1, 2164.3, 2109.0, 1991.2, 1802.5, 1548.2, 1264.0, 1004.2, 807.9, 688.2 and 631.0.
The power drops of rapidly as the threshold increases from 3 to 5, as futility stopping increases from 3%
to 65%. When, on average, two test treatments are taken into stage 2, that is when the fixed threshold
is somewhere between 3.5 and 4 (overall sample size between 1548.2 and 1264.0), the power is lower
(between 78.7% and 65.4%) than the analogous setting in Figure 1 (86.6%). The early outcome effect sizes
and distribution are such that a fixed threshold that on average picks two treatments at interim, also stops
for futility so often that it reduces the power considerably compared to a design that always takes only two
treatments.
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Figure 2: Probability of rejection of at least one elementary hypothesis (◦; solid line), futility stopping (dot-
ted line), selection probabilities (dashed lines) and expected total sample size (•; solid line) for thresholds
on a standardized z-scale in the range 0 to 6.
5.1.3 Continuous early and binary final outcome
The implementation described here has focused on normal outcome measures for both early and final out-
comes. However, if one or other outcomewere binary the changes necessary to implement this new scenario
are relatively straightforward. For instance, instead of using days of poor control over 26 weeks as the final
outcome measure, we might use a threshold based on this outcome. If this was the case, then success or
failure of the treatment could be determined for each study participant, based on some a priori threshold
for the number of days that one might expect to maintain control over the 26 week period. For the sake of
example, let us consider the failure rate to be 50% in the control group, and 45% (75µg), 45% (150µg),
40% (300µg) and 40% (600µg), at each dose respectively. Given that every other facet of the design were
the same as the first setting in the COPD example, then this design can be implemented using the following
code.
treatsel.sim(n=list(stage1=100,stage2=300),
effect=list(early=c(0,0.68,0.82,0.95,0.91),
final=c(0.50,0.45,0.45,0.40,0.40)),
outcome=list(early="N",final="B"),
nsim=10000,corr=0.4,seed=145514,select=2,
level=0.025,ptest=c(3,4))
This gives an overall rejection probability of 76.99%, by changing the outcome argument for the
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treatsel.sim function of Section 5.1.2 to list(early="N",final="B") and the vector of fi-
nal effect sizes to c(0.50,0.45,0.45,0.40,0.40).
5.2 Clinical trials in oncology with subgroup selection
Jenkins et al (2011) suggested designs for adaptive seamless phase II/III designs for oncology trials using
correlated survival endpoints. Designs of this type can be implemented relatively straightforwardly using
the subpop.sim function. Here we explore some design properties for a typical scenario from amongst the
many that Jenkins et al (2011) explored. We assume early and final time-to-event outcomes with a hazard
ratio of 0.6 in the subgroup and 0.9 in the full population for both, and a correlation between endpoints of
0.5; in the setting of an oncology trial, the endpoints might be progression free and overall survival. We
set the stage 1 sample size to 100 patients per arm and the stage 2 sample size to 300 patients per arm,
if we progress in the full population, and if we progress in the subgroup only to 200 patients per arm.
The subgroup prevalence is fixed at 0.3. Using the futility rule for selection at interim, with limits for the
subgroup and full population both set to 0, this scenario can be implemented using the following code:
subpop.sim(n=list(stage1=100,enrich=200,stage2=300),
effect=list(early=c(0.6,0.9),final=c(0.6,0.9)),
sprev=0.3,outcome=list(early="T",final="T"),
nsim=10000,corr=0.5,seed=1234,select="futility",
selim=c(0,0),level=0.025,method="CT-SD")
The “method=CT-SD” option implements the combination test method with Spiessens and Debois
testing procedure. Given test statistics at interim of S1 and S2 for the subgroup and the full population
respectively and rule limits (l1, l2), the futility rule implements the following options: (i) if S1 < l1 and
S2 < l2, continue with a co-primary analysis, (ii) if S1 < l1 and S2 >= l2, continue in the subgroup only,
(iii) if S1 >= l1 and S2 < l2, continue in the full population only and (iv) if S1 ≥ l1 and S2 ≥ l2, stop for
futility. Results from running this code are as follows (omitting the parts describing the setup):
simulation of test statistics:
expectation early: sub-pop = -1.46 : full-pop = -0.58
expectation final stage 1: sub-pop = -1.46 : full-pop = -0.58
expectation final stage 2: sub-pop only = -3.76 : full-pop only = -1.01
expectation final stage 2, both groups selected: sub-pop = -2.52 : full-pop = -1.01
weights: stage 1 = 0.5 and stage 2 = 0.87
hypotheses rejected and group selection options at stage 1 (n):
Hs Hf Hs+Hf Hs+f n n%
sub 2225 0 0 2225 2309 23.09
full 0 48 0 54 227 2.27
both 5370 1658 1636 5407 6987 69.87
total 7595 1706 1636 7686 9523 -
% 75.95 17.06 16.36 76.86 95.23 -
reject Hs and/or Hf = 76.65%
The output reports that in 75.95%, 17.06% and 16.36% of the simulations we rejected in the subgroup,
full population and both, respectively. The final two columns give a breakdown of the selections made
at the interim analysis; 23.09% of the simulations were continued in the subgroup only, 2.27% in the full
population only, 69.87% in both and 4.77% were stopped for futility. A concise summary of this table can
be obtained for further analysis, by assigning to an output object and accessing the results using the syntax
output$results.
It is informative in understanding the futility rule, to run the above code for a grid of futility rule limits
in the range 0 to -3; the results of this for each option are summarized in Table 2, where the notation lS and
lF indicate the limits for the subgroup and full population, respectively.
From Table 2 it is clear that as lS becomes more negative the subgroup is selected progressively less
often and similarly as lF becomes more negative, then, it is selected progressively more often. The balance
between the two limits determines overall power in this setting. With a strong effect in the subgroup and a
much weaker effect in the full population, the best strategy is to always, unless stopping for futility, test in
the subgroup at the final analysis. For the grid of values tested here this is best achieved when lF = −3 and
lS = 0.
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Table 2: Selection probabilities, probability of futility stopping and power (probability of rejecting at least
one elementary null hypothesis) for a range of values of lS and IF .
lF lS Selection (%) Futility (%) Power (%)
Subgroup Full Both
0 0 23.1 2.3 69.9 4.8 76.7
0 -1 11.4 16.2 55.8 16.7 58.8
0 -2 2.3 45.1 26.5 26.1 34.2
0 -3 0.1 66.0 6.0 27.9 20.7
-1 0 60.0 0.4 32.3 7.3 83.9
-1 -1 37.4 4.0 29.7 29.0 61.4
-1 -2 12.3 16.5 16.9 54.2 30.3
-1 -3 1.5 28.4 4.8 65.4 13.8
-2 0 84.9 0.0 7.4 7.7 88.6
-2 -1 60.1 0.3 7.2 32.4 65.0
-2 -2 24.1 2.4 5.6 68.0 29.2
-2 -3 4.4 5.3 2.1 88.2 8.0
-3 0 91.6 0.0 0.7 7.7 89.7
-3 -1 66.7 0.0 0.7 32.6 66.0
-3 -2 28.6 0.1 0.6 70.7 28.8
-3 -3 5.6 0.4 0.3 93.7 6.1
6 Discussion
Adaptive seamless designs are recognized as a tool to increase the efficiency of clinical development pro-
grammes by combining features of learning and confirming in a single trial, while traditional development
programmes would have investigated these in separate trials. However, their implementation is more in-
volved than traditional designs (see e.g. Quinlan and Krams (2006) for a discussion). One aspect is the
planning which is more complex often requiring extensive Monte Carlo simulations (Benda et al, 2010;
Friede et al, 2010). Here we presented a unified framework for adaptive seamless designs with treatment or
subpopulation selection. Furthermore, we developed a flexible and yet efficient simulation model. This, as
all other methods discussed, can accommodate interim selection informed by an early outcome rather than
the final one. Furthermore, we demonstrate how the R package asd, freely available from CRAN, can be
used to evaluate and compare operating characteristics of various designs.
There are of course some limitations. Here we focused very much on hypothesis testing, although the
estimation of the treatment effects is equally important. There has been some interest in improved estimators
in adaptive seamless designs with treatment (Posch et al, 2005; Brannath et al, 2009; Bowden and Glimm,
2014; Stallard and Kimani, 2018) or subgroup selection (Kimani et al, 2015, 2018), in particular in more
recent years.
With regard to interim decisions we considered here only fairly straightforward rules although Bayesian
statistics (e.g. predictive probabilities (Brannath et al, 2009)) are also used as the basis for interim decisions.
Currently we consider expanding the R package asd in this direction.
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Appendix. Derivation of data simulation models
We consider first treatment selection designs. Let µˆ
(i)
kj be the estimate for treatment k, k = 0, 1, . . . ,K with
k = 0 corresponding to control, at stage j , j = 1, . . . , J , for endpoint i, i = 1, 2.
Assume, as often holds at least asymptotically, that µˆ
(i)
kj is normally distributed with
µˆ
(i)
kj ∼ N(µ
(i)
k , (I
(i)
kj )
−1),
with
cov(µˆ
(i)
kj , µˆ
(i)
k′j′ ) = 0, k 6= k
′,
cov(µˆ
(i)
kj , µˆ
(i)
kj′ ) = (I
(i)
kmax{j,j′})
−1
and
cov(µˆ
(i)
kj , µˆ
(i′)
kj′ ) = ρ
√
(I
(i)
kmax{j,j′})
−1(I
(i′)
kmax{j,j′})
−1, i 6= i′.
For independent normal random variables with known variance σ2, we have I
(i)
kmax{j,j′} = σ
2/n
(i)
kj
where n
(i)
kj is the number of observations at look j for treatment k on endpoint i.
Let θˆ
(i)
kj = θˆ
(i)
kj − θˆ
(i)
0j , k = 1, . . . ,K , I
(i)
kj = ((I
(i)
kj )
−1 + (I
(i)
0j )
−1)−1 and S
(i)
kj = θˆ
(i)
kj I
(i)
kj .
Let λ
(i)
kj = (I
(i)
kj )
−1/(I
(i)
0j )
−1. If λ
(i)
kj is constant, say equal to λ, and I
(i)
kj = I
(i)
k for all k (for a single
sample of known-variance normals, this is equivalent to assuming that sample sizes are the same for all
experimental treatments). In this case, considering first a single endpoint, we get


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where the variance matrix is given by
Σ =

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. . . I
(1)
2
1+λ
I
(1)
2
1+λ · · ·
I
(1)
2
1+λ I
(1)
2
· · ·
I
(1)
J
I
(1)
J
1+λ · · ·
I
(1)
J
1+λ
I
(1)
J
1+λ I
(1)
J
. . .
...
...
. . .
. . .
I
(1)
J
1+λ
I
(1)
J
1+λ · · ·
I
(1)
J
1+λ I
(1)
J


.
Note that we can rewrite the right hand side of () as
N
(
I(1) ⊗ θ(1),Σ(GS)(I(1))⊗ Σ
(CS)
K (
1
1 + λ
)
)
where I(1) and θ(1) denote respectively the vectors (I
(1)
1 , . . . , I
(1)
J )
′, and (θ(1)1, . . . , θ(1)K)
′ and
Σ
(CS)
K (r) =


1 r · · · r
r 1
. . .
...
...
. . .
. . . r
r · · · r 1


and
Σ(GS)(I)(1) =


I
(1)
1 I
(1)
1 · · · I
(1)
1
I
(1)
1 I
(1)
2 · · · I
(1)
2
...
...
. . .
...
I
(1)
1 I
(1)
2 · · · I
(1)
J


denote variance matrices of the K ×K complex symmetric form and of that obtained in the usual group-
sequential setting.
When both endpoints are considered, the vector
(S
(1)
11 , . . . , S
(1)
K1, . . . , S
(1)
1J , . . . , S
(1)
KJ , S
(2)
11 , . . . , S
(2)
K1, . . . , S
(2)
1J , . . . , S
(2)
KJ)
′
is normally distributed with mean(
θ(1) ⊗ I(1)
θ(2) ⊗ I(2)
)
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and variance(
Σ(GS)(I(1)) ρΣ(GS)(I(12))
ρΣ(GS)(I(12)) Σ(GS)(I(2))
)
⊗ Σ
(CS)
K (
1
1 + λ
)
where is a J-dimensional vector with I
(12)
j =
√
I
(1)
j I
(2)
j , j = 1, . . . , J .
We consider next designs with subgroup selection. In analogy to the notation used above, now let θˆ
(i)
kj
be the estimate the treatment effect in subgroup k, k = 1, . . . ,K at stage j , j = 1, . . . , J , for endpoint i,
i = 1, 2. We will typically consider the case of K = 2, with k = 2 corresponding to the entire population
and k = 1 corresponding to a subgroup comprising a proportion τ of the entire population.
Let (I
(i)
kj )
−1 denote the variance of θˆ
(i)
kj and let S
(i)
k j = θˆ
(i)
kj I
(i)
kj .
As above, we will assume that the θˆ
(i)
kj are normally distributed with mean θ
(i)
k and variance (I
(i)
kj )
−1
with
cov(θˆ
(i)
kj , θˆ
(i)
k′j′ ) = (I
(i)
max{k,k′}max{j,j′})
−1
and
cov(θˆ
(i′)
kj , θˆ
(i)
k′j′) = ρ(I
(i)
max{k,k′}max{j,j′}I
(i)
max{k,k′}max{j,j′})
−1/2, i 6= i′.
Denote I
(i)
j2 by I
(i)
j and assume further that I
(i)
j1 = τI
(i)
j for i = 1, 2, j = 1, . . . , J (see Spiessens and
Debois), then
(S
(1)
11 , S
(21)
1 , . . . , S
(1)
1J , S
(1)
2J , S
(2)
11 , S
(2)
21 , . . . , S
(2)
1J , S
(2)
2J )
′
is normally distributed with mean(
θ(1) ⊗ I(1)
θ(2) ⊗ I(2)
)
and variance(
Σ(GS)(I(1)) ρΣ(GS)(I(12))
ρΣ(GS)(I(12)) Σ(GS)(I(2))
)
⊗ Σ(GS)
(
τ
1
)
where I(i) = (I
(i)
1 , . . . , I
(i)
J )
′, I12 = (I
(12)
1 , . . . , I
(12)
J )
′ with I
(12)
j =
√
I
(1)
j I
(2)
j , θ
(i) = (θ
(i)
1 , θ
(i)
2 ) and
Σ(GS)(I) and Σ
(CS)
K (r) are as defined above.
If more than two subgroups are considered, or if these are nested in some other way than the second
being a subset of the first, the last matrix can be modified accordingly to reflect this.
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